BioSET Announces Initiation of Clinical Trials for AMPLEX Osteo-Promotive Bone Graft System for Spine Fusion

ROCKVILLE, MD--(Marketwire - December 02, 2008) - BioSurface Engineering Technologies, Inc. [BioSET], a privately held company developing synthetic peptide growth factor mimetics for advanced tissue repair, reported today that two pilot clinical trials, one in the United States and one in Canada, have been initiated with the Company's AMPLEX osteo-promotive bone graft system. AMPLEX is a novel combination medical device that incorporates BioSET's B2A, a BMP-2 growth factor analog, with ultra high-grade ceramic bone scaffold for use in lumbar interbody spine fusion surgery.
MORE ON THIS TOPIC